中国医药（600056）(600056.SH)发布公告，近日，公司下属全资子公司天方药业（600253）有限公司 (简称"天方药业")收到国家药品监督管理局核准签发的瑞舒伐他汀依折麦布片(I)《药品注册证书》。瑞 舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症(HoFH)。依折麦布与 瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 ...

格隆汇12月24日丨中国医药(600056.SH)公布，近日，公司下属全资子公司天方药业有限公司收到国家 药监局核准签发的瑞舒伐他汀依折麦布片(I)《药品注册证书》。药品名称：瑞舒伐他汀依折麦布片(I)， 证书编号：2025S03793。 (三)截至本公告披露日，该药品累计投入约 2,439 万元人民币(未经审计)。 (二)国家药监局于 2024 年 8 月受理山东朗诺制药有限公司该药品的注册申请(受理号 CYHS2402864)， 2024 年 12 月受理天方药业有限公司该产品的药品上市许可持有人变更申请(受理号 CYHB2402147)。 (一)瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症(HoFH)。依折麦 布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2025-089 号 中国医药健康产业股份有限公司 关于子公司获得药品注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，中国医药健康产业股份有限公司（以下简称"公司"）下属全资子公 司天方药业有限公司（以下简称"天方药业"）收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的瑞舒伐他汀依折麦布片（I）（以下简称"该 药品"）《药品注册证书》，现将有关情况公告如下： 一、注册证书基本信息 药品名称：瑞舒伐他汀依折麦布片（I） 受理号：CYHS2402864、CYHB2402147 证书编号：2025S03793 剂型：片剂 规格：每片含瑞舒伐他汀钙 10mg（按 C₂₂H₂₈FN₃O₆S 计）与依折麦布 10mg 二、药品其他相关情况 （一）瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性 高胆固醇血症（HoFH）。依折麦布与瑞舒伐他汀钙两药联合可协同增效，能增 加降血脂疗效并降低心血管事件。 （二）国家药监局于 2024 年 8 ...

瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症（HoFH）。依折麦 布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 人民财讯12月24日电，中国医药（600056）12月24日公告，下属全资子公司天方药业（600253）收到国 家药品监督管理局核准签发的瑞舒伐他汀依折麦布片（I）《药品注册证书》。 ...

Core Viewpoint - China Medical (600056.SH) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical Co., Ltd., has received the drug registration certificate for Rosuvastatin Ezetimibe Tablets from the National Medical Products Administration, indicating a significant advancement in its product portfolio aimed at treating high cholesterol levels and familial hypercholesterolemia [1] Group 1 - The approved drug, Rosuvastatin Ezetimibe Tablets, is primarily used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH) [1] - The combination of Ezetimibe and Rosuvastatin calcium is expected to enhance lipid-lowering efficacy and reduce cardiovascular events [1]

Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, received approval from the National Medical Products Administration for the drug Rosuvastatin and Ezetimibe Tablets, which may enhance the product line and accumulate experience, although sales may not meet expectations [1] Group 1: Product Approval - The drug is a combination of Rosuvastatin Calcium 10mg and Ezetimibe 10mg in tablet form [1] - The manufacturing company is Shandong Longnuo Pharmaceutical Co., Ltd. [1] Group 2: Financial Investment - The total investment in the drug up to the announcement date is approximately 24.39 million yuan [1] Group 3: Sales Projections - The projected sales for the drug in 2024 across three major terminals and six markets is approximately 1.46 million yuan (only for the original research) [1] - The projected sales for the first three quarters of 2025 is approximately 23.53 million yuan [1]

Core Insights - The 10th Health China Pharmaceutical Chain Development Forum was held in Taizhou, Jiangsu, focusing on industry transformation and growth opportunities under the theme "Health Marketing for Everyone" [1][3] - The forum, hosted by Yangtze River Pharmaceutical Group, has evolved over ten years from policy discussions to model innovation and now to ecological co-construction, highlighting the collaborative journey of thousands of chain partners [3] - Yangtze River Pharmaceutical's Chairman Xu Haoyu emphasized the company's commitment to building a health ecosystem through strategic capabilities and collaboration with partners, aiming to set a benchmark for industry development [3] Industry Trends - The pharmaceutical retail industry is currently undergoing a critical transformation from product sales to health service provision, with compliance, digitalization, and service orientation identified as key development directions [3] - Industry experts provided insights on data trends, consumer changes, and innovative models to help chain operations break through challenges, focusing on brand empowerment and terminal traffic conversion [3] - The forum concluded with Yangtze River Pharmaceutical's commitment to a comprehensive empowerment plan and strategic product lines to build a collaborative and win-win "He Xi Ecological Circle," addressing the industry's "increased revenue without increased profit" dilemma [3][4] Forum Objectives - The He Xi Forum serves as a high-end platform for national pharmaceutical chain enterprises to discuss hot topics, challenges, and pain points in the industry, sharing the latest development trends and exploring new models for high-quality growth [4]

Core Insights - The pharmaceutical packaging machinery industry plays a crucial role in ensuring the safety and effectiveness of drugs from production to consumer delivery, with a market size in China projected to grow from 2.76 billion yuan in 2015 to 6.854 billion yuan in 2024, reflecting a compound annual growth rate (CAGR) of 10.63% [1][12][13] Industry Overview - Pharmaceutical packaging machinery includes various automated devices used for packaging drugs and medical devices, such as blister packaging machines, filling machines, and labeling machines [3][12] - The industry is driven by increasing demand due to an aging population and rising consumer spending [1][12] Market Trends - The industry is evolving towards high precision, flexibility, integration, and data connectivity, driven by technological innovation and market demand [1][12] - Future developments will focus on achieving sub-millimeter precision in critical areas like sterile packaging and implantable device sealing [16] - There is a trend towards flexible and modular designs to accommodate small batch and customized production needs [16] - Integration of packaging machinery with upstream and downstream production systems is expected to enhance operational efficiency and data traceability [17] Policy Environment - National policies are promoting green development and intelligent manufacturing in the machinery sector, providing clear directions for transformation and support for the pharmaceutical packaging machinery industry [5][6] Industry Chain - The industry chain consists of upstream raw materials (steel, mechanical components), midstream manufacturing, and downstream applications in the pharmaceutical sector [6][8] Competitive Landscape - The industry features a diverse competitive landscape with both international brands like Grief and domestic companies like Springlight Intelligent Equipment Group gaining market share through innovation and localized services [13] - Key players include Springlight Intelligent, Zhejiang Haotong Machinery, and several others, focusing on high-quality, intelligent packaging solutions [13][14][15]

Core Viewpoint - The announcement from Jiukang Bio indicates that a major shareholder has completed a share buyback plan, which may reflect confidence in the company's future performance and could influence market perception positively [1] Group 1 - Jiukang Bio announced that its major shareholder, Yiyao Investment, has completed a share buyback plan from June 23, 2025, to December 22, 2025 [1] - The total shares acquired through the buyback amounted to 2,926,000 shares, representing 0.499% of the company's total share capital [1] - The total amount spent on the buyback was 39,719,980.00 yuan [1]

每经AI快讯，九强生物12月23日晚间发布公告称，持股5%以上的股东中国医药投资有限公司计划自 2025年6月23日至2025年12月22日，通过集中竞价交易、大宗交易等法律法规允许的方式增持公司股 票，计划增持公司股份金额不少于3000万元（含）人民币，增持所需资金为自有资金。公司于2025年12 月22日收到持股5%以上股东国药投资出具的《中国医药投资有限公司关于北京九强生物技术股份有限 公司股份增持计划实施完毕的函》。截至本公告披露日，本次增持计划已实施完毕，国药投资以集中竞 价交易的方式共增持股份2,926,000股，占公司总股本的0.499%，占剔除公司回购账户股份后总股本的 0.502%，增持金额为39,719,980.00元人民币。 （记者 曾健辉） 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 ...